Komori
Astena Holdings (8095) · InitiativeAdvanced

Management Quality Reform and Talent Development for Glocalization

First written in FY2016. 7 of 11 entries say "Advanced", first in FY2019. Latest entry: FY2024.

11entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2019 – FY20222017: 120172018: 120182019: 020192020: 220202021: 220212022: 020222023: 220232024: 220242025: 1
Same theme, other companies
Strengthening corporate capabilities through globalization and training for change-ready talentA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「Under these circumstances, our Group is also reviewing the medium-term management plan on a rolling basis, including the Medium-Term Management Plan Rolling (2025-2027), in light of progress against targets and other factors, with a view to achieving the Group’s long-term vision.」

    Based on progress against targets for the long-term vision, the 2025-2027 medium-term management plan was reviewed on a rolling basis.
  2. FY2024-Q2RestatedAnnual report

    「Accordingly, by ending the arrangement under which the former Representative Director and President concurrently served as representative director of the holding company Astena Holdings Co.,Ltd. and the operating companies Spela Pharma Inc. and Iwaki Pharmaceutical Sakura Plant Co., Ltd., we intend to separate management from execution. In addition, the former Representative Director, who was actively involved from the acquisition of both companies through subsequent investment decisions, will personally lead the business, thereby accelerating overall growth in the fine chemicals business.」

    The plan to accelerate growth in the fine chemicals business by ending concurrent service as representative director of the holding company and operating companies and separating management from execution continues to be presented.
  3. FY2024-Q1AdvancedAnnual report

    「Accordingly, by ending the arrangement under which the former Representative Director and President concurrently served as representative director of the holding company Astena Holdings Co.,Ltd. and the operating companies Spela Pharma Inc. and Iwaki Pharmaceutical Sakura Plant Co., Ltd., we intend to separate management from execution. In addition, the former Representative Director, who was actively involved from the acquisition of both companies through subsequent investment decisions, will personally lead the business, thereby accelerating overall growth in the fine chemicals business.」

    To accelerate growth in the fine chemicals business, a structure was presented in which concurrent service as representative director of the holding company and operating companies would be ended and management would be separated from execution.
  4. FY2023-Q1Lingering Effects of Delays in Management ImprovementAnnual report

    「The effects of delays in management improvement initiatives that occurred at certain operating companies in the previous fiscal year remained, and consolidated earnings did not recover.」

    At certain operating companies, the effects of delays in management improvement initiatives that occurred in the previous fiscal year remained during the current quarter.
  5. FY2022AdvancedAnnual report

    「Under these circumstances, our Group is also reviewing the medium-term management plan on a rolling basis, including the Medium-Term Management Plan Rolling (2023-2025), in light of progress against targets and other factors, with a view to achieving the Group’s long-term vision.」

    Management quality reform based on a holding company structure and 5 businesses progressed to a review of the 2023-2025 medium-term management plan on a rolling basis.
  6. FY2021-Q1AdvancedAnnual report

    「Our Group is pursuing its businesses toward achieving the Group’s long-term vision, Astena 2030 “Diversify for Tomorrow.” As we expand our businesses, including through several M&A transactions in recent years, we will transition to a holding company structure on 1 June 2021 (scheduled) to enable more agile Group management.」

    Against the backdrop of M&A and business expansion aimed at achieving Astena 2030, the transition to a holding company structure scheduled for 1 June 2021 was set out in concrete terms.
  7. FY2020AdvancedAnnual report

    「Our Group is accelerating the pace of transformation by integrating and operating business divisions that had previously been managed independently into a structure of operating companies for each business segment through the transition to a holding company structure scheduled for June 2021. At the same time, we are enhancing management of corporate resources by thoroughly reviewing business processes, redefining various internal systems and rules, and updating business systems and other infrastructure.」

    The transition to a holding company structure was specified with a deadline, and the integration into a structure of operating companies, redefinition of business processes and internal systems, and system updates were set out as specific reform measures.
  8. FY2020-Q1AdvancedAnnual report

    「Following a review of its management reporting classifications and internal organization, the Group changed its reportable segments as follows from the first quarter of the current consolidated fiscal year.」

    Management classifications and internal organizational structures were reviewed, resulting in the concrete division and consolidation of reporting segments.
  9. FY2019AdvancedAnnual report

    「Our Group is accelerating the pace of transformation by integrating and operating business divisions that had previously been managed independently in line with the value chains of each product. At the same time, we are enhancing management of corporate resources by thoroughly reviewing business processes, redefining various internal systems and rules, and updating business systems and other infrastructure.」

    We continued to enhance corporate resource management through integrated operation of business divisions, redefinition of business processes and internal systems, and updates to business systems. Separately, we also made ¥499 million in investments to update information systems.
  10. FY2017RestatedAnnual report

    「While preserving the sound corporate culture cultivated over many years, we recognize that revising behavior patterns characteristic of mature companies and reforming and improving management quality are extremely important issues.」

    The revision of behavior patterns characteristic of mature companies and management quality reform continue to be positioned as important issues in executing the medium-term strategy.
  11. FY2016First statedAnnual report

    「We recognize that revising behavior patterns characteristic of mature companies and reforming and improving management quality are extremely important issues. We will promote these efforts, including by establishing a new talent development program aimed at promoting “glocalization” across the Group.」

    The revision of behavior patterns characteristic of mature companies, improvement of management quality, and establishment of a talent development program aimed at glocalization were described for the first time in concrete terms as issues to be addressed.
Moved together

"Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production" moved the same way as this thread, in the same document, in 7 of its 11 moves.

776655★123456
  1. ★This thread
  2. 1Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production7×
  3. 2Expanding Sales of Generic Pharmaceutical Ingredients and New Materials Through Customer Proposals7×
  4. 3Developing New Customers, Proprietary Products and Overseas Customers Through the New Organization6×
  5. 4Introduction of Performance-Linked and Restricted Stock Compensation Plans6×
  6. 5Strengthening the CMC contract research business through the acquisition of all shares in スペラファーマ5×
  7. 6Stable Supply of Pharmaceuticals, Capital Investment and Production Efficiency Improvements5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Astena Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Management Quality Reform and Talent Development for Glocalization | Astena Holdings Co.,Ltd. (8095) | Komori